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Abstract
Objective To determine the rate of early discontinuation and
non-publication of randomised controlled trials involving patients
undergoing surgery.
DesignCross sectional observational study of registered and published
trials.
Setting Randomised controlled trials of interventions in patients
undergoing a surgical procedure.
Data sources The ClinicalTrials.gov database was searched for
interventional trials registered between January 2008 and December
2009 using the keyword “surgery”. Recruitment status was extracted
from the ClinicalTrials.gov database. A systematic search for studies
published in peer reviewed journals was performed; if they were not
found, results posted on the ClinicalTrials.gov results database were
sought. Email queries were sent to trial investigators of discontinued
and unpublished completed trials if no reason for the respective status
was disclosed.
Main outcome measures Trial discontinuation before completion and
non-publication after completion. Logistic regression was used to
determine the effect of funding source on publication status, with
adjustment for intervention type and trial size.
ResultsOf 818 registered trials found using the keyword “surgery”, 395
met the inclusion criteria. Of these, 21% (81/395) were discontinued
early, most commonly owing to poor recruitment (44%, 36/81). The
remaining 314 (79%) trials proceeded to completion, with a publication
rate of 66% (208/314) at a median time of 4.9 (interquartile range 4.0-6.0)
years from study completion to publication search. A further 6% (20/314)
of studies presented results on ClinicalTrials.gov without a corresponding
peer reviewed publication. Industry funding did not affect the rate of
discontinuation (adjusted odds ratio 0.91, 95% confidence interval 0.54
to 1.55) but was associated with a lower odds of publication for completed
trials (0.43, 0.26 to 0.72). Investigators’ email addresses for trials with
an uncertain fate were identified for 71.4% (10/14) of discontinued trials
and 83% (101/122) of unpublished studies. Only 43% (6/14) and 20%
(25/122) replies were received. Email responses for completed trials
indicated 11 trials in press, five published studies (four in non-indexed
peer reviewed journals), and nine trials remaining unpublished.
Conclusions One in five surgical randomised controlled trials are
discontinued early, one in three completed trials remain unpublished,
and investigators of unpublished studies are frequently not contactable.
This represents a waste of research resources and raises ethical
concerns regarding hidden clinical data and futile participation by patients
with its attendant risks. To promote future efficiency and transparency,
changes are proposed to research governance frameworks to overcome
these concerns.
Introduction
Trial discontinuation, non-publication, and non-contactable
investigators represent a potential waste of research resources,
leading to hidden trial data and ethical concerns for study
participants.1 With decreasing health budgets and finite
resources, such wastage is unsustainable and strategies to
increase efficiency may be required.
In general research populations, high rates of discontinuation
and non-publication of randomised controlled trials have been
identified as common problems.2-4 The extent of this waste in
surgery specific studies is unknown. Surgical randomised
controlled trials have methodological challenges similar to trials
of novel drugs. Additional difficulties can be encountered
through introduction of new equipment (including minimally
invasive versus open surgery) or material and lack of equipoise
when comparing operative and non-operative options, which
may lead to greater expense and suboptimal efficiency in trial
conduct.5 Interventions including surgical technique, use of
technology, and optimal perioperative care require novel
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strategies for delivery that cannot be controlled with placebo as
in conventional drug trials. Such design problems can lead to
poor recruitment, futility, and adverse events, which may
predispose to waste. Industry funding has previously been
suggested as a contributing factor to waste.2-4 However,
collaboration with industry developers and funders is an
important source of surgical innovation,6 which may present a
unique dynamic in surgery specific studies.
A greater understanding of the factors leading to waste will
guide future allocation of resources and allow funders to foster
mutually beneficial relationships with research teams to
maximise research capacity. Previous work has included
strategies to promote transparency in randomised controlled
trials, including trial registration on publicly available
databases.7 These resources (for example, ClinicalTrials.gov)
provide an open access medium to assess outcomes of trials and
to permit assessment of publication bias.8 9 This study aimed to
determine the rate of discontinuation and non-publication of
surgical randomised controlled trials and the feasibility of
contacting trial investigators.
Methods
Objectives and outcome measures
The objective of this study was to determine the rate of
discontinuation and non-publication of randomised controlled
trials involving patients undergoing surgery. For this study, we
defined wastage of resources in three domains, which we
subsequently used as the main outcome measures:
discontinuation (versus completion); non-publication (versus
publication); and feasibility of contacting trial investigators for
both discontinued and unpublished studies. Although success
of email contact has not been tested as an outcome in this context
before, this is a logical way for patients, clinicians, and trialists
to obtain information about relevant trials that have been
discontinued or remain unpublished.
Data source
ClinicalTrials.gov is a web based registration system and
database including more than 174 000 clinical trials.10 The
database was launched in 2000 and is maintained and quality
controlled by the United States National Library of Medicine.
Data are provided by study investigators and sponsors, who are
expected to provide updates throughout the trial’s lifecycle.
Each record provides information relating to recruitment status,
study design, funding, and participants. Records are identifiable
by a unique national clinical trial (NCT) number.
Definitions
ClinicalTrals.gov defines registered studies on the basis of
current recruitment status11; this formed the basis for definitions
and inclusions used in this paper. We included terminated,
withdrawn, or suspended studies in the “discontinued” group
(see table 1⇓ for complete definitions), with completed studies
forming the “completed” group. We excluded trials with status
“unknown,” “active, not recruiting,” or “enrolling by invitation.”
For the purposes of this study, we defined industry funded trials
as any trial receiving commercially sourced funding, including
investigator initiated, industry sponsored trials.
We used two definitions for publication, to represent a spectrum
of reporting methods. The primary definition was publication
of a complete manuscript in a peer reviewed journal, identified
through a systematic search. The secondary definition was
availability of results in the ClinicalTrials.gov results database,
when no primary publication was found. This was not included
in the primary definition, as the principles of peer review,
compliance with reporting standards (for example, CONSORT
statement), and detailed reporting are not upheld in the
ClinicalTrials.gov results database.12 Two authors (SJC and AB)
independently classified studies by detailed intervention type
(grouped under main headings of non-device operative, device,
or pharmacological intervention), with consensus discussion in
case of disagreement.
Study inclusion criteria
We queried the ClinicalTrials.gov advanced search facility by
using the keyword “surgery” for non-paediatric, phase III-IV
clinical trials registered between 1 January 2008 and 31
December 2009, using recruitment status definitions (table 1⇓).
The keyword search was a pragmatic decision based on time
efficiency and the likelihood that it would identify most relevant
studies; no other systematic search term for surgical trials within
ClinicalTrials.gov exists. We defined surgery as any procedure
involving an incision through an external body surface. We
included phase III/IV randomised controlled trials including a
preoperative, intra-operative, or postoperative intervention
applied to adult patients undergoing a surgical procedure in any
surgical specialty. Phase III/IV studies assess effectiveness in
large patient groups, and subsequent publication is expected.
We excluded phase II studies, as these are typically safety
assessments before phase III studies, for which publication is
not routinely planned.We excluded studies involving paediatric
patients, as we judged that these are likely to have recruitment
problems more in keeping with involving children than surgical
techniques and warrant separate analysis. We included trials
registered between 1 January 2008 and 31 December 2009 with
a final confirmed status by 31 December 2011.
Search strategy
We did the ClinicalTrials.gov search on a single day (18
December 2013) to account for daily changes to the database.
We screened the title and trial summary of each study to remove
non-randomised and duplicated entries (BS and HM, checked
by SJC). We then made a detailed evaluation of each record to
confirm trial inclusion (BS and HM, checked by AB). In cases
of discrepancy, a third author reviewed the record and consensus
was achieved by discussion.
Publication search
The time elapsing from the latest possible completion date (31
December 2011) to the time of the search for publication (10
August 2014) allowed a minimum of 31 months for journal
submission, peer review, and editorial processes. We initially
reviewed each ClinicalTrials.gov record to identify links to
relevant publications (BS, checked by SJC). Authorsmay choose
to provide this information by updating the record once the
study is published. If no such link was identified, we searched
Medline via PubMed by using the following characteristics:
NCT number, trial title, author names, institutions, and keywords
(BS, checked by SJC). We subsequently searched for
publications not identified using PubMed via the Scopus
bibliographic database by using a comparable strategy (BS,
checked by SJC). Scopus has a wide coverage and encompasses
citations listed in both PubMed and Embase. We evaluated
matches according to trial design, sample size, dates of
recruitment, study hypotheses, and nature of intervention, as
described in the ClinicalTrials.gov database. We considered a
trial as published if it was catalogued in print or in press. If we
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found no peer reviewed journal publication, we sought reporting
of results within the ClinicalTrials.gov results database.
Contact email search
For discontinued trials without a stated reason on
ClinicalTrials.gov and for completed studies with no identified
publication, we sought a contact email address. We searched
for publications authored by the trial investigator identified on
the register by using PubMed and Scopus databases through
examination of previous publications by investigator name,
location, and field of expertise. We sent a standardised email
to seek clarification of the reason for discontinuation or current
publication status, with one reminder scheduled two weeks later
(BS and HM, checked by SJC). We deemed trial investigators
to be non-contactable and considered completed trials to be
unpublished if we received no response within the total four
weeks. If a contact email address was not found, if no response
was received, or if the email address provided was inactive, we
did a further Google Scholar and Google search using the trial
registration number, investigator name, or both (BS, checked
by AB). If these failed and a sponsoring industry name was
provided, we requested details through either a company email
address or a generic online contact form. We calculated a final
response rate by dividing the total number of replies from all
sources by the number of trials for which we sought contact.
Statistical analysis
We used the χ2 test to compare differences in trial design
variables between groups. We considered differences to be
statistically significant if P was less than 0.05. To test for the
effect of these variables together on discontinuation and
publication status, we used adjusted binary logistic regression.
The binary outcome targets were firstly discontinuation (versus
completion) and secondly non-publication (versus publication);
we used primary publication (in a peer reviewed journal) for
this modelling process. Selection of variables used for
adjustment of these models and their categorisation was
pre-planned, irrespective of statistical significance at the
univariable level; we judged these adjustment variables to be
key surrogate markers of important differing trial design. The
main explanatory variable was funding status (industry versus
non-industry), adjusted for intervention type (drug or medical
device versus non-drug) and number of patients in the trial
(≥100 versus <100 patients). Further variables were not added
or tested within models to avoid overlap and over-adjustment
in this exploratory analysis. This produced an odds ratio and
95% confidence interval, which if greater than 1.0 indicated a
greater likelihood of trial completion or publication and if less
than 1.0 indicated lower likelihood.We used SPSS version 21.0
for analysis.
Results
Characteristics of included studies
The initial search identified 818 trials, of which 395 were
included in the final analysis after exclusions (fig 1⇓). The most
frequently represented specialties were gastrointestinal surgery
(23%), trauma and orthopaedic surgery (23%), ophthalmology
(13%), and cardiothoracic surgery (13%) (table 2⇓). Table 3⇓
shows detailed intervention classes for all included trials. The
median number of study participants was 100 (interquartile
range 51-205, range 1-6000). The primary site/affiliation of the
principle investigator originated from 39 countries across six
continents.
Discontinuation
Table 4⇓ shows trials’ characteristics according to study
completion status. Of 395 clinical trials, 314 (79%) were
completed and 81 (21%) were discontinued. This represented
77 008 (83.1%) and 15 626 (16.9%) study participants
respectively (calculated from actual or target registration data
in ClinicalTrials.gov). Of the discontinued trials, 72 (89%) were
terminated, 8 (10%)werewithdrawn, and 1 (1%)was suspended.
We found no significant differences between completion status
for funding type, intervention type, number of participants, or
blinding. More discontinued trials were multicentre (36%
(112/314) completed v 51% (41/81) discontinued; P=0.034) and
international (9% (28/314) v 17% (14/81); P=0.042).
Fourteen (17.3%) discontinued studies did not provide reasons
on ClinicalTrials.gov (fig 2⇓). We identified contact email
addresses for 71% (10/14) and received replies from 60% (6/10)
of queries sent, giving an overall responding email rate of 43%
(6/14). Including these responses, the most common reasons
for discontinuation were poor recruitment (44%; 36/81), lack
of continued funding (10%; 8/81), and termination due to
negative results (10%; 8/81) (table 5⇓). Industry funding was
not a predictor of discontinuation (adjusted odds ratio 0.91, 95%
confidence interval 0.54 to 1.55; P=0.735) (table 6⇓).
Non-publication of completed studies
Table 7⇓ shows characteristics of the 314 completed studies,
according to publication status. The median time from study
completion to publication search date was 4.9 (interquartile
range 4.0-6.0, minimum 2.7) years. Of 314 completed trials,
we initially identified 192 as published following searches on
PubMed and Scopus databases. We sought contact email
addresses for the remaining 122 unpublished trials, for which
101 email addresses were identified and contacted, with the
remaining 21 email addresses not found (fig 3⇓). Of authors
contacted, 25/101 (25%) replies were received, giving an overall
responding email rate of 20% (25/122). These replies identified
11 studies in press and five published studies (four in
non-indexed peer reviewed journals). We subsequently
considered these published, yielding a revised total of 208/314
(66%) published studies in peer reviewed journals. The
remaining responses identified a further nine trials as
unpublished (table 8⇓). Combining these nine with 21 studies
without a contact email address, 60 with no reply to contact,
and 16 with an inactive email address generated a total of 106
unpublished trials according to the definition of primary
publication (34%; 106/314).
Of the 314 completed studies, 69 (22%) had results on the
ClinicalTrials.gov results database. A peer reviewed publication
was also available for 49 of these; the remaining 20 (6%) studies
reported in the online entry only. This means that the rate of
non-publication fell to 27% (86/314) when we considered the
primary (peer reviewed journal) and secondary
(ClinicalTrials.gov results only) publication standards together.
Of the 69 studies with results, 66 (96%) had an email contact,
two (3%) had a telephone contact only, and one (1%) had no
contact details. For 245 studies on ClinicalTrials.gov that were
completed without results, no contact details were available on
the online entry.
Industry funding was significantly associated with reduced
likelihood of publication (adjusted odds ratio 0.43, 0.26 to 0.72;
P=0.001), and sample size of 100 or more patients was
associated with increased likelihood of publication (1.71, 1.03
to 2.84; P=0.038) (table 6⇓).
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Discussion
This study identified a considerable waste of resources in
interventional trials related to patients undergoing surgery. One
in five surgical randomised controlled trials were discontinued
early and one in three completed trials remained unpublished
at a median of 4.9 years. Difficulty obtaining information from
corresponding research teams compounded these losses.
Although not quantified by this study, this wastage is likely to
represent a poor use of financial resources for funders, host
institutions, and commissioning bodies. In addition, further
non-financial and ethical costs include a loss of knowledge
through hidden data and patients being placed at potential risk
without delivery of accessible research benefits.1 The most
common reason for discontinuation was poor recruitment of
participants, which is a persistent problem and aligns with
previous reports describing this challenge for a wider range of
clinical trials.3 Some reasons for early discontinuation may have
led to preservation of resources rather than wastage. Carefully
considered termination due to positive or negative results, safety
data, or clinical developments is likely to save future resources,
whereas poor recruitment, trial conduct problems, or withdrawal
of management groups represents wasted resources.
Strengths and weaknesses of this study
Problems in trial delivery and scientific design of interventional
surgical trials may not be comparable to those of drug trials.5
This study included only surgical specialties on the basis that
the surgical community must urgently consider trial design,
conduct, and resource allocation. Through inclusion of a broad
range of surgical specialties and related intervention types, the
relevance to research teams across multiple surgical specialties
is wide and generalisable. Conversely, this is also an inherent
limitation of the study, as the results do not permit a detailed
assessment of exactly where in the research pathway, which
surgical specialty, or which intervention should be targeted. It
is likely that not all surgical randomised controlled trials were
captured by this study, partly because we used a pragmatic
search strategy based only on the keyword “surgery”. More
importantly, a recent analysis of 10 high impact surgical journals
showed that, contrary to guidelines, 34.9% of 246 published
randomised controlled trials were not registered on a clinical
trials database and would therefore not be identified by our
search strategy.7 8However this finding should not directly affect
the rate of non-publication, which is a function of registered
trials only. It is also feasible that not all published trials were
identified, although if publications were available beyond the
comprehensive search strategy used in this study, their lack of
visibility presents an additional barrier contributing to resource
wastage. Although the study period chosen (2008-09) represents
the modern trials era, trials designed in the present day may
have overcome some of the wastage problems, although the
situation may have also worsened. As this can be explored only
after publication status can be reliably assessed, this study
represents the most modern knowledge available and is able to
influence current trial design.
The relatively short follow-up period used by this study may
have contributed to the low publication rate. Although our study
represents a modern time period, the earlier time frame used by
Kasenda et al (2000-03) allowed for a longer median follow-up
of 11.6 (range 8.8-12.6) years, compared with our shorter
median period of 4.9 years with a minimum time of 2.7 years.3
A longer period, which accounts for studies with long follow-up
times, may have further increased the publication rate in our
study. The nature of these delays is unknown and should be
subject to future linked research to minimise them when
possible. The effect on the relevance of a study’s results,
especially when considering introduction of novel surgical
technologies and perioperative drugs (which are likely to have
short term outcome measures), justifies use of a shorter
follow-up period in this study.
This study highlights difficulty in tracing study investigators.
Contact details for completed but unpublished studies were
unavailable from the ClinicalTrials.gov entry, suggesting
systematic removal. A ClinicalTrials.gov record should be
considered to have been published in the public domain, and
information should not be removed from this at a later date.
Additional barriers to contact exist, which may have limited
response rates in this study during the search for further
information, such as investigators changing surnames, moving
institution before study completion, or changing email addresses.
Furthermore, the quality of results in the ClnicalTrials.gov entry
has not yet been systematically analysed for compliance with
reporting guidelines.
Strengths andweaknesses in relation to other
studies
Rosenthal and colleagues recently reported a 43%
discontinuation rate and a 44% non-publication rate from
surgical randomised controlled trials registered by six ethics
committees in three countries between 2000 and 2003 (Canada,
Germany, Switzerland).13 Our large, contemporary analysis
supports these findings by using an international trials
registration database; Rosenthal reported 127 surgical trials
from three countries, compared with 395 trials from 39 countries
in six continents in our study. We additionally sought to assess
feasibility of contacting trial investigators across this wider
geographical landscape, which better represents the position of
patients and clinicians seeking results, rather than direct contact
from a research ethics committee alone.
Before these, studies assessing non-publication of clinical trials
did not analyse surgical studies separately, so their application
to surgical trialists was unclear.2 4 14-18A previous study including
1017 registered randomised controlled trials from a broad
specialty base found that poor recruitment was the most frequent
reason for discontinuation (9.9%; 101/1017) and that industry
sponsors were associated with non-publication (adjusted odds
ratio 1.68, 1.20 to 2.34).3 A recent cross sectional analysis of
non-publication of large randomised trials from
ClinicalTrials.gov included only trials with more than 500
patients from any specialty.2 This study found a 29% (171/585)
non-publication rate, which was significantly associated with
industry funding, and a ClinicalTrials.gov only publication rate
of 6%. These are in keeping with our results, which showed a
non-publication rate of 33.8% and a ClnicalTrials.gov only
publication rate of 6.4%. This demonstrates importance in both
large and small clinical trials. As larger trials were more likely
to be published, the specific challenges encountered in often
smaller surgery specific trials leading to this attrition may be
different and require further definition. Aligned with this, a
recent study assessing the rate of non-publication in trials
relating to medical vaccines reported similar results, with a
non-publication rate of 50.4%.4Our study confirms the relevance
of these findings in surgery specific studies and provides direct
evidence to the surgical community of the need for reform.
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Meaning of study: implications for clinicians
and policy makers
The advent of clinical trial registration has provided the
necessary foundation to increase transparency and awareness
of research methodology. Taken together with previous work
quantifying trial outcomes in other medical specialties,2 5 14-18
this study shows an urgent need to solve problems of research
capacity and resource wastage, hidden or lost knowledge through
trial discontinuation and non-publication, and difficulties relating
to communication with people responsible for conducting such
trials. As the extent of these problems continues to becomemore
apparent, new strategies to combat them are needed to augment
current international, national, and local research governance
frameworks. Input from all stakeholders is needed, including
funding and commissioning bodies, regulatory groups (both
medical and governmental), ethics review boards, and the public
and private institutions hosting such clinical research activities.
This study found that both multicentre and international trials
were associated with higher rates of discontinuation, which
highlights difficulty in their delivery. Completed studies with
larger patient numbers were more likely to be published, so
investment in their delivery is worthwhile. As national surgical
networks develop to deliver multicentre trials, their potential to
deliver robust international multicentre trials remains untested.19
If successful, these could greatly increase the generalisability
of findings and, with well functioning networks, could speed
recruitment.
Industry funding had the strongest association with
non-publication of completed studies, although in commonwith
previous studies we are unable to identify the reasons for this.
It may be a function of industry held data, conduct of industry
trials, or research teams failing to publish. Surgical collaboration
with industry through an appropriate governance framework is
still likely to be beneficial for patients, driving innovation in
devices and drugs, and policy makers should work to ensure
healthy collaborative relationships. Funders should also be
willing to support trials with potentially negative results, which
could include trials discontinued early. Although investigators’
responses from this study identified negative findings as a barrier
to publication, several journals now carry a commitment to
publish negative studies that have high methodological rigour.20
Recommendations and future research
The optimum framework to deliver surgical trials that are likely
to succeed in a timely fashion is unclear, and a considerable
need exists for surgery specific guidance in this area. All funders
should expect value for money and timely delivery of such
studies. For surgical trials, this may involve targeting the limited
resources available to research teams who have the resources
and infrastructure to deliver larger multicentre trials. In this
way, efficiency is increased, maximising use of the available
research capacity. This should not hinder the establishment of
new researchers, but rather they should enter an existing
structural framework that will help them to deliver across a
multicentre platform.
A ban on publishing industry funded research, which has been
suggested, could harm surgical innovation and should be
discouraged.21 Rather, frameworks should be put in place to
match industry funders to independent, clinically driven
researchers who can deliver trials that are relevant to patients
and who can hold data independently. In any collaboration with
industry, academic investigators must remain free to publish
their findings without risk of a sponsor’s veto, in keeping with
good publishing practices.22
Internationally, the World Medical Association’s “Declaration
of Helsinki,”23 detailing the ethical principles of medical research
involving humans, includes the statement that “Authors have a
duty to make publicly available the results of their research on
human subjects.” This ethical duty should be incorporated into
agreements put in place by research funding and commissioning
bodies, with regulatory oversight and enforcement. Holding
trial data in secure and independent trials units may prevent any
intentional or unintentional losses in the future. This also
promotes the importance of data sharing, ideally through open
access data platforms. Such structures would also overcome
difficulties encountered in communication with corresponding
investigators, which can be time consuming, inefficient, and
often fruitless (as shown in this study), further reducing
transparency. Even in cases in which no journal paper is written,
ensuring open access publication of datasets for completed
studies will satisfy this obligation.
To enable improved communication, a permanent contact should
be made publicly available from the point of trial registration.
In future, this contact may be best suited to a permanent “clinical
data controller” role within the clinical trial regulatory
framework, whereby a nominated person identified by the
initiator of the study ensures access to trial data. This will ensure
that contact is not lost as named principal investigators move
on in their careers. This may be of great interest to patients, who
can track results and query investigators directly if data remain
non-published.
Finally, patients recruited to surgical trials are probably not
aware of or informed about the risk of early termination or
non-publication. Ethically, patients and the wider medical
profession must consider this serious problem. A fully informed
decision to participate in a trial is an absolute requirement, and
persistence of these problems may further hinder recruitment
to trials through a perception of futility and altered balance of
risks. Careful consideration and guidance around this matter is
needed.
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Tables
Table 1| ClinicalTrials.gov definitions for recruitment status of randomised trials11
DefinitionRecruitment status
Included in this study
The clinical study has ended normally, and participants are no longer being examined or treated (that is, the
“last subject, last visit” has occurred)
Completed
The clinical study has stopped recruiting or enrolling participants early, but it may start againSuspended
The clinical study has stopped recruiting or enrolling participants early and will not start again. Participants are
no longer being examined or treated
Terminated
The clinical study stopped before enrolling its first participantWithdrawn
Excluded from this study
The clinical study is ongoing (that is, participants are receiving an intervention or being examined), but potential
participants are not currently being recruited or enrolled
Active, not recruiting
A clinical study that selects its participants from a population, or group of people, decided on in advance by
the researchers. These studies are not open to everyone who meets the eligibility criteria, but only to people
in that particular population, who are specifically invited to participate
Enrolling by invitation
A clinical study in ClinicalTrials.gov with a status of “recruiting,” “not yet recruiting,” or “active, not recruiting”
and whose status has not been confirmed within the past two years. Studies with an unknown recruitment
status are considered open studies or closed studies, depending on their last recorded recruitment status
Unknown
No definition available“Temporarily not available for expanded access”
“No longer available for expanded access”
“Approved for marketing”
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Table 2| Surgical specialty of 395 randomised controlled trials included in study
No (%) of trialsSurgical specialty
92 (23)Gastrointestinal surgery
91 (23)Trauma and orthopaedics
52 (13)Ophthalmology
51 (13)Cardiothoracic surgery
30 (8)Gynaecology
18 (5)Urology
14 (4)Breast surgery
11 (3)Vascular surgery
10 (3)Neurosurgery
5 (1)Otolaryngology
5 (1)Plastic surgery
4 (1)Oral and maxillofacial surgery
12 (3)Other
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Table 3| Intervention class of 395 randomised controlled trials included in this study
No (%) trialsIntervention class
42 (11)1) Operative intervention; non-device (total):
13 (3)1A Operative versus non-operative intervention
29 (7)1B Surgical technique (non-device)
106 (27)2) Intervention with device (total):
44 (11)2A Implantable therapeutic device (permanent)
18 (5)2B Non-implantable therapeutic device
44 (11)2C Operative (non-therapeutic, temporary, or access) or diagnostic device
247 (63)3) Pharmacological interventions (total):
75 (19)3A (i) Perioperative analgesics
8 (2)3A (ii) Perioperative anti-emetics
11 (3)3B Reduction and prevention of infection
28 (7)3C Reduction and prevention of haemorrhage
6 (2)3D Fluid management
14 (4)3E Nutrition
12 (3)3F Reduction and prevention of thrombosis
45 (11)3G Reduction and prevention of other disease-specific morbidity
18 (5)3H Adjuvant therapeutic treatment
30 (8)3I Other
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Table 4| Characteristics of completed and discontinued trials. Values are numbers (percentages) unless stated otherwise
P valueTotal (n=395)Completed (n=314)Discontinued (n=81)Characteristic
Funding:
0.548229182 (79)47 (21)Non-industry
166132 (80)34 (20)Industry
Intervention:
0.2514230 (71)12 (29)Operative
10682 (77)24 (23)Device
247202 (82)45 (18)Pharmacological
No of centres:
0.034226186 (82)40 (18)Single centre
153112 (73)41 (27)Multicentre
1616 (100)0 (0)Missing
Sample size:
0.663184145 (79)39 (21)<100
206166 (81)40 (19)≥100
53 (60)2 (40)Missing
Recruitment:
0.042340273 (80)67 (20)National
4228 (67)14 (33)International
1313 (100)0 (0)Missing
Blinding:
0.14912190 (74)31 (26)None
9480 (85)14 (15)Single*
176141 (80)35 (20)Double
43 (75)1 (25)Missing
Percentages total across rows.
*Investigator, assessor, or patient blinding.
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Table 5| Reasons for discontinuation of 81/395 surgical randomised controlled trials
No (%)Reason for non-completion
36 (44)Insufficient/poor patient recruitment
8 (10)Lack of funding to continue trial
8 (10)Trial terminated early owing to negative results/futility
7 (9)Withdrawal of trial management or clinical investigators
4 (5)Trial administration or conduct problems
4 (5)Trial lost clinical relevance
3 (4)Trial product/device/drug withdrawn from market
2 (2)Trial termination based on safety or toxicity data
1 (1)Trial terminated early owing to positive results
8 (10)Missing
14/81 did not disclose reason for termination on ClinicalTrials.gov; emails were identified and sent to 10/14 authors, with no contact available for remaining 4/14.
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Table 6| Adjusted logistic regression for effect of industry funding on trial discontinuation and publication of completed trials
MultivariableUnivariable
P valueOdds ratio (95% CI)P valueOdds ratio (95% CI)
Discontinuation
Funding:
ReferenceReferenceNon-industry
0.7350.91 (0.54 to 1.55)0.9921.00 (0.61 to 1.65)Industry
Intervention:
ReferenceReferenceOperative
0.5581.29 (0.55 to 3.06)0.4491.37 (0.61 to 3.07)Device
0.2091.65 (0.76 to 3.62)0.1231.80 (0.85 to 3.78)Pharmacological
Sample size:
ReferenceReference<100 patients
0.7041.10 (0.66 to 1.84)0.6631.12 (0.68 to 1.83)≥100 patients
Publication
Funding:
ReferenceReferenceNon-industry
0.0010.43 (0.26 to 0.72)0.0030.49 (0.30 to 0.78)Industry
Intervention:
ReferenceReferenceOperative
0.6530.80 (0.30 to 2.13)0.4540.70 (0.27 to 1.78)Device
0.7000.64 (0.34 to 2.07)0.3900.69 (0.29 to 1.62)Pharmacological
Sample size:
ReferenceReference<100 patients
0.0381.71 (1.03 to 2.84)0.2261.34 (0.84 to 2.14)≥100 patients
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Table 7| Characteristics of published and unpublished completed trials. Values are numbers (percentages) unless stated otherwise
P valueTotal (n=314)Published (n=208)Unpublished (n=106)Characteristics
Funding:
0.003182133 (73)49 (27)Non-industry
13275 (57)57 (43)Industry
Intervention:
0.6863022 (73)8 (27)Operative
8254 (66)28 (34)Device
202132 (65)70 (35)Pharmacological
No of centres:
0.398186130 (70)56 (30)Single centre
11273 (65)39 (35)Multicentre
165 (31)11 (69)Missing
Sample size:
0.22514591 (63)54 (37)<100 patients
166115 (69)51 (31)≥100 patients
32 (67)1 (33)Missing
Recruitment:
0.678273186 (68)87 (32)National
2818 (64)10 (36)International
134 (31)9 (69)Missing
Blinding:
0.2349058 (64)32 (36)None
8048 (60)32 (40)Single*
141100 (71)41 (29)Double
32 (67)1 (33)Missing
Percentages total across rows.
*Investigator, assessor, or patient blinding.
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Table 8| Reasons for non-publication received from corresponding authors of 20 completed randomised controlled trials who replied to
email information requests*
NoReason for non-publication
11Study in press but not available on PubMed.
3Publication efforts abandoned following failed submission(s)
2Lack of time, resources, or personnel
1Clinician authors decided not to publish owing to negative results
1Study terminated early
1Study still ongoing
1Reason not disclosed by author
*Five additional responses disclosed a peer reviewed publication (four in non-PubMed indexed journals), leading to a total of 25 investigators’ responses for
completed trials.
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Figures
Fig 1 Inclusion and exclusion criteria of clinical trials
Fig 2 Discontinued trials: authors’ email response
Fig 3 Completed trials: identified publications and authors’ email response
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;349:g6870 doi: 10.1136/bmj.g6870 (Published 9 December 2014) Page 15 of 15
RESEARCH
